

# Table of Contents

---

## Ham-Wasserman Lecture

- 1 AL amyloidosis: from molecular mechanisms to targeted therapies  
*Giampaolo Merlini*

## Acute Lymphocytic Leukemia: New Approaches in Management

- 13 Minimal residual disease in adult ALL: technical aspects and implications for correct clinical interpretation  
*Monika Brüggemann and Michaela Kotrova*
- 22 Current management of Philadelphia chromosome positive ALL and the role of stem cell transplantation  
*Farhad Ravandi*
- 28 Progress in adult ALL: incorporation of new agents to frontline treatment  
*Jessica Leonard and Wendy Stock*

## Acute Myeloid Leukemia: How Can We Improve Upon Standard Therapy?

- 37 Classification and risk assessment in AML: integrating cytogenetics and molecular profiling  
*Matahi Moarii and Elli Papaemmanuil*
- 45 How and when to decide between epigenetic therapy and chemotherapy in patients with AML  
*Hervé Dombret and Raphael Itzykson*
- 54 The role of targeted therapy in the management of patients with AML  
*Alexander E. Perl*

## Bone Marrow Failure: Acquired

- 66 Clinical implications of somatic mutations in aplastic anemia and myelodysplastic syndrome in genomic age  
*Jaroslav P. Maciejewski and Suresh K. Balasubramanian*
- 73 Aging, hematopoiesis, and the myelodysplastic syndromes  
*Stephen S. Chung and Christopher Y. Park*
- 716 Acquired ribosomopathies in leukemia and solid tumors  
*Adrianna Vlachos*

## Bone Marrow Failure: Inherited

- 79 Old and new tools in the clinical diagnosis of inherited bone marrow failure syndromes  
*Allison H. West and Jane E. Churpek*
- 88 Inherited bone marrow failure syndromes: considerations pre- and posttransplant  
*Blanche P. Alter*
- 96 Treatment of inherited bone marrow failure syndromes beyond transplantation  
*Rodrigo T. Calado and Diego V. Clé*

## Chronic Myeloid Leukemia: Where Are We in the Current TKI Era?

- 102 Treatment-free remission in CML: who, how, and why?  
*Francois-Xavier Mahon*

- 110 Cardiovascular care of patients with chronic myeloid leukemia (CML) on tyrosine kinase inhibitor (TKI) therapy  
*Mary C. Barber, Michael J. Mauro, and Javid Moslehi*
- 115 Novel approaches to therapy in CML  
*Ravi Bhatia*

## Common Clinical Questions in Cancer-Associated Venous Thromboembolism

- 121 Incidental venous thromboembolism: is anticoagulation indicated?  
*Marcello Di Nisio and Marc Carrier*
- 128 When can we stop anticoagulation in patients with cancer-associated thrombosis?  
*Agnes Y. Y. Lee*
- 136 Direct oral anticoagulants: now also for prevention and treatment of cancer-associated venous thromboembolism?  
*Ingrid Pabinger and Julia Riedl*

## Common Hematologic Consults in Pregnancy

- 144 Thrombocytopenia in pregnancy  
*Douglas B. Cines and Lisa D. Levine*
- 152 Iron deficiency in gynecology and obstetrics: clinical implications and management  
*Christian Breyman and Michael Auerbach*
- 160 Preventing venous thromboembolism during pregnancy and postpartum: crossing the threshold  
*Leslie Skeith*
- 168 Evidence-Based Minireview: Diagnosis and management of postpartum ovarian vein thrombosis  
*Bethany T. Samuelson Bannow and Leslie Skeith*

## Congenital and Acquired Neutropenia

- 172 New monogenic disorders identify more pathways to neutropenia: from the clinic to next-generation sequencing  
*Seth J. Corey and Usua Oyarbide*
- 181 Chronic neutropenia in LGL leukemia and rheumatoid arthritis  
*Tal Gazitt and Thomas P. Loughran, Jr.*
- 187 Non-chemotherapy drug-induced neutropenia: key points to manage the challenges  
*Brian R. Curtis*

## Controversies in Myeloma

- 194 Shall we treat smoldering multiple myeloma in the near future?  
*Ola Landgren*
- 205 Is molecular remission the goal of multiple myeloma therapy?  
*Faith E. Davies*
- 212 Fixed duration vs continuous therapy in multiple myeloma  
*Heinz Ludwig and Niklas Zojer*

## Controversies in Venous Thromboembolism: To Treat or Not to Treat

- 223 Controversies in venous thromboembolism: to treat or not to treat superficial vein thrombosis  
*Jan Beyer-Westendorf*
- 231 Should we diagnose and treat distal deep vein thrombosis?  
*Helia Robert-Ebadi and Marc Righini*
- 237 Symptomatic subsegmental pulmonary embolism: to treat or not to treat?  
*Marc Carrier and Fredrikus A. Klok*

## Dilemmas in Pediatric Hematologic Malignancy

- 242 Pediatric leukemia susceptibility disorders: manifestations and management  
*Lisa J. McReynolds and Sharon A. Savage*
- 251 Crisis management in the treatment of childhood acute lymphoblastic leukemia: putting right what can go wrong (emergency complications of disease and treatment)  
*Rachael Hough and Ajay Vora*
- 259 Incorporation of nonchemotherapeutic agents in pediatric acute lymphoblastic leukemia  
*Lewis B. Silverman*

## Emerging Issues in Clinical Care in Thalassemia

- 265 Iron overload in thalassemia: different organs at different rates  
*Ali T. Taher and Antoine N. Saliba*
- 272 Impact of bone disease and pain in thalassemia  
*Antonio Piga*
- 278 New therapeutic targets in transfusion-dependent and -independent thalassemia  
*M. Domenica Cappellini and Irene Motta*

## Evolving Strategies in Aggressive B-Cell Lymphoma

- 284 Tailoring front-line therapy in diffuse large B-cell lymphoma: who should we treat differently?  
*Andrew Davies*
- 295 Evidence-Based Minireview: Current treatment of double hit and double expressor lymphoma  
*Patrick M. Reagan and Andrew Davies*
- 298 Primary mediastinal B-cell lymphoma: biology and evolving therapeutic strategies  
*Kieron Dunleavy*
- 304 Optimizing therapy for mantle cell lymphoma  
*Peter Martin*

## Hodgkin Lymphoma: New Insights and New Approaches

- 310 Signaling pathways and immune evasion mechanisms in classical Hodgkin lymphoma  
*W. Robert Liu and Margaret A. Shipp*
- 317 Emerging role of novel therapies in Hodgkin lymphoma: proceed with caution  
*Nancy L. Bartlett*

- 324 Nodular lymphocyte-predominant Hodgkin lymphoma: a unique disease deserving unique management  
*Dennis A. Eichenauer and Andreas Engert*

## Individualizing Therapy in Chronic Lymphocytic Leukemia

- 329 The mutational landscape of chronic lymphocytic leukemia and its impact on prognosis and treatment  
*Gianluca Gaidano and Davide Rossi*
- 338 Optimizing frontline therapy of CLL based on clinical and biological factors  
*Kirsten Fischer and Michael Hallek*
- 346 How should we sequence and combine novel therapies in CLL?  
*Matthew S. Davids*
- 354 Evidence-Based Minireview: Safety profiles of novel agent therapies in CLL  
*Inhye E. Ahn and Matthew S. Davids*

## Indolent Lymphoma: How Understanding Disease Biology Is Influencing Clinical Decision-Making

- 358 Follicular lymphoma: are we ready for a risk-adapted approach?  
*Brad S. Kahl*
- 365 Toward personalized treatment in Waldenström macroglobulinemia  
*Jorge J. Castillo and Steven P. Treon*
- 371 Improved biological insight and influence on management in indolent lymphoma. Talk 3: update on nodal and splenic marginal zone lymphoma  
*Catherine Thieblemont*

## It All Starts Here: Disorders of Primary Hemostasis

- 379 Advances in the diagnosis and treatment of Von Willebrand disease  
*Ruchika Sharma and Veronica H. Flood*
- 385 Hereditary thrombocytopenias: a growing list of disorders  
*Patrizia Noris and Alessandro Pecci*
- 400 Management of newly diagnosed immune thrombocytopenia: can we change outcomes?  
*Cindy E. Neunert*

## Lessons Learned From Quality Improvement Initiatives in Sickle Cell Disease

- 406 Five lessons learned about long-term pain management in adults with sickle cell disease  
*Joshua J. Field*
- 412 Improving Emergency Department-Based Care of Sickle Cell Pain  
*Jeffrey A. Glassberg*
- 418 Rigorous and practical quality indicators in sickle cell disease care  
*Suzette O. Oyeku and Elissa Z. Faro*

## Management of Sickle Cell Disease: Present and Future

- 423 Cardiovascular complications in patients with sickle cell disease  
*Mark T. Gladwin*

- 431 Evidence-Based Minireview: What is the role of screening for pulmonary hypertension in adults and children with sickle cell disease?  
*Shaina M. Willen and Mark T. Gladwin*
- 435 Chronic organ failure in adult sickle cell disease  
*Elliott Vichinsky*
- 440 Evolving treatment paradigms in sickle cell disease  
*Ramasamy Jagadeeswaran and Angela Rivers*

## Myelodysplastic Syndromes: Understanding the Current Treatment Landscape

- 447 Uncoding the genetic heterogeneity of myelodysplastic syndrome  
*R. Coleman Lindsley*
- 453 Current treatment algorithm for the management of lower-risk MDS  
*Aristoteles Giagounidis*
- 460 Incorporating novel approaches in the management of MDS beyond conventional hypomethylating agents  
*Olatoyosi Odenike*

## Myeloproliferative Neoplasms: New Insights in the Current Treatment Paradigm

- 470 Myeloproliferative neoplasms: from origins to outcomes  
*Jyoti Nangalia and Anthony R. Green*
- 480 What are the current treatment approaches for patients with polycythemia vera and essential thrombocythemia?  
*Alessandro M. Vannucchi and Paola Guglielmelli*
- 489 Current treatment algorithm for the management of patients with myelofibrosis, JAK inhibitors, and beyond  
*Claire N. Harrison and Donal P. McLornan*

## Novel Therapeutics in Myeloma

- 498 Management of multiple myeloma in the newly diagnosed patient  
*María-Victoria Mateos and Jesús F. San Miguel*
- 508 Management of multiple myeloma in the relapsed/refractory patient  
*Pieter Sonneveld*
- 518 Emerging options in multiple myeloma: targeted, immune, and epigenetic therapies  
*Shaji Kumar*

## Practical Aspects of Acute and Chronic Pain Management in Sickle Cell Disease

- 525 Optimizing the care model for an uncomplicated acute pain episode in sickle cell disease  
*Paul Telfer and Banu Kaya*
- 534 Pain-measurement tools in sickle cell disease: where are we now?  
*Deepika S. Darbari and Amanda M. Brandow*
- 542 Evidence-Based Minireview: Responsiveness of Patient-Reported Outcome Measurement Information System (PROMIS) pain domains and disease-specific patient-reported outcome measures in children and adults with sickle cell disease  
*Susanna Curtis and Amanda M. Brandow*

- 546 Targeting novel mechanisms of pain in sickle cell disease  
*Huy Tran, Mihir Gupta, and Kalpna Gupta*

## The Challenge of Primary and Secondary Central Nervous System Lymphoma

- 556 Biology of CNS lymphoma and the potential of novel agents  
*James L. Rubenstein*
- 565 Therapy of primary CNS lymphoma: role of intensity, radiation, and novel agents  
*Andrés José María Ferreri*
- 578 Secondary CNS relapse in diffuse large B-cell lymphoma: defining high-risk patients and optimization of prophylaxis strategies  
*Kerry J. Savage*

## The Changing Landscape of Hemophilia Therapy

- 587 Hemophilia gene therapy comes of age  
*Lindsey A. George*
- 595 Using pharmacokinetics to individualize hemophilia therapy  
*Alfonso Iorio*
- 605 Novel alternate hemostatic agents for patients with inhibitors: beyond bypass therapy  
*Margaret V. Ragni*

## The Expanding Role of Immunotherapy in Non-Hodgkin Lymphoma

- 610 Role of the microenvironment across histological subtypes of NHL  
*Karin Tarte*
- 618 Harnessing the power of the immune system in non-Hodgkin lymphoma: immunomodulators, checkpoint inhibitors, and beyond  
*Stephen M. Ansell*
- 622 Developing T-cell therapies for lymphoma without receptor engineering  
*Melanie Grant and Catherine M. Bollard*

## Therapeutic Apheresis as an Immunomodulatory Tool

- 632 Plasma exchange in thrombotic microangiopathies (TMAs) other than thrombotic thrombocytopenic purpura (TTP)  
*Jeffrey L. Winters*
- 639 Extracorporeal photopheresis: cellular therapy for the treatment of acute and chronic graft-versus-host disease  
*Jennifer Schneiderman*
- 645 HLA donor-specific antibodies in allogeneic hematopoietic stem cell transplantation: challenges and opportunities  
*Douglas E. Gladstone and Maria P. Bettinotti*

## Thrombocytopenia in Hospitalized Patients

- 651 Thrombocytopenia in hospitalized patients: approach to the patient with thrombotic microangiopathy  
*Marie Scully*

660 Assessing thrombocytopenia in the intensive care unit: the past, present, and future  
*Ryan Zarychanski and Donald S. Houston*

667 HITs and misses in 100 years of heparin  
*Lawrence Rice*

### Thrombosis, Devices, and Interventions

674 Anticoagulation with VADs and ECMO: walking the tightrope  
*Leslie Raffini*

681 Thrombectomy and thrombolysis for the prevention and treatment of postthrombotic syndrome  
*Suresh Vedantham*

686 Inferior vena cava filter use and patient safety: legacy or science?  
*William Geerts and Rita Selby*

### When Graft Versus Tumor Fails: The Biology and Treatment of Relapse after Allogeneic Stem Cell Transplantation

693 Graft versus tumor effects and why people relapse  
*J. H. Frederik Falkenburg and Inge Jedema*

699 Pharmacologic agents to prevent and treat relapse after allogeneic hematopoietic cell transplantation  
*Robert J. Soiffer and Yi-Bin Chen*

708 Cells to prevent/treat relapse following allogeneic stem cell transplantation  
*Andrew C. Dietz and Alan S. Wayne*